@BazsaLess than expected a bit of an understatement Baz.\MSB...

@Bazsa

Less than expected a bit of an understatement Baz.\

MSB spent more than the upfront on Rem-L product alone in FY20 for GvHD and ARDs ready
"Manufacturing commercialization (25,309)" USD
So Novartis has got in for basically free upfront, as note that "future" product costs will be theirs.
Seems to me they have pounced on a weak position created by FDA.

So Baz, how long before you actually see some cash revenues/$$ from those milestones? THE REAL MONEY
What is the milestone structure?
Put some timelines on it will ya, as at $40m a Q burn, this "deal" is worth just 2 quarters so far when / if completed.

One take out and a big one I note is the focus finally on manufacturing SCALE
after SI talking only about it for 7 years in every annual report, finally it looks like Novartis will need to see some actual action.
Given SI has stated this needs to start in pre-clinical; (3D and Serum Free)

How long before you can actually use this mythical 3D machine?
Put some timelines on that too would ya.